Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Agrima Mian, MBBS, MD, Wei Wei, MS, Brian T. Hill, MD, Betty K. Hamilton, MD, Allison M. Winter, MD, Jack Khouri, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Faiz Anwer, MD, Aaron T. Gerds, MDMS, Matt Kalaycio, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Navneet S. Majhail, MD MS

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-137801

Published: 2020

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Anne K Hubben, MD, Lisa Rybicki, MS, Kristin Ricci, MD, Navneet S. Majhail, MD MS, Matt Kalaycio, MD, Betty K. Hamilton, MD, Brian T. Hill, MD, Allison M. Winter, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Robert M. Dean, MD, Ronald Sobecks, MD, Chakra P Chaulagain, MD, Hien D. Liu, MD, Jack Khouri, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140456

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Agrima Mian, MBBS, MD, Wei Wei, MS, Allison M. Winter, MD, Jack Khouri, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Aaron T. Gerds, MD MS, Robert M. Dean, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4452.

https://doi.org/10.1182/blood-2019-127087

Published: 2019

Journal Articles

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Agrima Mian, MBBS, MD, Albert Aboseif, DO, Wei Wei, MS, Rajshekhar Chakraborty, MD, Jack Khouri, MD, Joslyn Rudoni, PharmD, Allison M. Winter, MD, Sonam Patel, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Brad Pohlman, MD, Stephanie Berg, DO, James R. Cook, MD PhD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD

Blood (2019) 134 (Supplement_1): 5248.

https://doi.org/10.1182/blood-2019-130396

Published: 2019

Journal Articles

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Allison M. Winter, MD, Kirsten M Boughan, DO, Jack Khouri, MD, Paolo Caimi, MD, Faiz Anwer, MD, Brenda Cooper, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Marcos de Lima, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 5705.

https://doi.org/10.1182/blood-2019-124602

Published: 2019

Journal Articles

The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Bartlomiej Przychodzen, Jack Khouri, MD, Heesun J. Rogers, MD PhD, Manja Meggendorfer, PhD, Anjali S. Advani, MD, Aziz Nazha, MD, Torsten Haferlach, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 5411.

https://doi.org/10.1182/blood-2019-128965

Published: 2019

Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD

Blood (2019) 134 (Supplement_1): 3148.

https://doi.org/10.1182/blood-2019-131400

Published: 2019

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Rajshekhar Chakraborty, MBBS, Hien D. Liu, MD, Lisa Rybicki, MS, Robert M. Dean, MD, Beth M. Faiman, PhDCNP, Matt Kalaycio, MD, Jack Khouri, MD, Christy J. Samaras, DO, Navneet S. Majhail, MD MS, Jason Valent, MD

Blood (2018) 132 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2018-99-113114

Published: 2018

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Blood (2017) 130 (Supplement 1): 2961.

https://doi.org/10.1182/blood.V130.Suppl_1.2961.2961

Published: 2017

Journal Articles

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Jack Khouri, MD, Thapa Bicky, MD, Frederic J. Reu, MD, Christy J. Samaras, DO, Hien D. Liu, MD, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 1819.

https://doi.org/10.1182/blood.V130.Suppl_1.1819.1819

Published: 2017

Journal Articles

Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists

Aditi Puri, MD, Ryan L. Stevenson, MD, Jack Khouri, MD, Raymond L. Comenzo, MD, Grace Shih-Hui Kao, MD, Andreas K. Klein, MD, Kenneth B. Miller, MD, Aaron Rosenberg, MD MS, Hedy Smith, MDPhD, Kellie A. Sprague, MD, Valerie Relias, PharmD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 2595.

https://doi.org/10.1182/blood.V124.21.2595.2595

Published: 2014

NARROW

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma

Activation of Autophagy in Models of SF3B1 Mutant MDS

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only